Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial vs Radical Nephrectomy Evaluated

Urol Oncol; ePub 2017 Dec 15; Venkatramani, et al

Partial nephrectomy (PN) resulted in better overall survival than radical nephrectomy (RN) in people with cT1b renal cell carcinoma (RCC), according to a study involving >12,000 individuals. This was not the case in those with cT2 RCC.

Participants with either cT1bN0M0 or cT2N0M0 RCC were identified between 2004 and 2013. They received either partial or radical nephrectomy. Investigators looked at overall survival, 30-day readmission rates, and 30- and 90-day mortality. Among the results:

  • Patients with cT1b tumors who underwent PN experienced better overall survival.
  • Unplanned 30-day readmission rate in patients undergoing PN regardless of tumor type was 4.2%, vs 2.9% for RN.
  • 30- and 90-day mortality rates were similar in the PN and RN cohorts.

Citation:

Venkatramani V, Koru-Sengul T, Miao F, et al. A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma-Analysis of a national cancer registry. [Published online ahead of print December 15, 2017]. Urol Oncol. doi:10.1016/j.urolonc.2017.11.008.

This Week's Must Reads

Healthcare.gov open enrollment picks up in Week 2, Weekly enrollment snapshot on CMS.gov

Trump administration takes contradictory actions on ACA, A press statement issued on CMS.gov.

Doctors raise concerns about administration's Part B drug plan, A CMS Fact Sheet on the ANPRM International Pricing Index Model for Medicare Part B Drugs

Guideline authors inconsistently disclose conflicts, Combs T et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.4730. Khan R et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.5106

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018